相似文献/References:
[1]邓艳,张伟.125I-碘酞酸盐临床应用进展[J].国际放射医学核医学杂志,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
Deng Yan,Zhang Wei.125I-iothalamate clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
[2]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[3]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[4]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[5]张丽花,蒋宁一.131I治疗Graves甲亢合并肝功能损害或血细胞减少的优势与风险[J].国际放射医学核医学杂志,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
Zhang Lihua,Jiang Ningyi.The advantage and risk of 131I treatment in hyperthyroidism combined with liver injury or blood cell reduction[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
[6]杨宝军.131I治疗甲亢合并特发性血小板减少性紫癜一例[J].国际放射医学核医学杂志,2015,39(6):511.[doi:10.3760/cma.j.issn.1673-4114.2015.06.017]
[7]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[8]胡小春,蒋宁一,李敬彦,等.硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响[J].国际放射医学核医学杂志,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
Hu Xiaochun,Jiang Ningyi,Li Jingyan,et al.Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
[9]杨翠红,刘金剑,褚丽萍,等.125I标记注射用干扰素α2b(假单胞菌)研究雾化吸入与肌肉注射的代谢及组织分布差异[J].国际放射医学核医学杂志,2015,39(3):191.[doi:10.3760/cma.j.issn.1673-4114.2015.03.001]
Yang Cuihong,Liu Jinjian,Chu Liping,et al.Pharmacokinetics and tissue distribution of interferon α2b（Pseudomonas putida）administered via atomization inhalation and intramuscular injection by 125I labeling[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):191.[doi:10.3760/cma.j.issn.1673-4114.2015.03.001]
[10]陈雪梅,周树云,范源,等.表没食子儿茶素没食子酸酯对131I辐射损伤所致甲减大鼠模型抗氧化体系的保护作用[J].国际放射医学核医学杂志,2015,39(4):311.[doi:10.3760/cma.j.issn.1673-4114.2015.04.009]
Chen Xuemei,Zhou Shuyun,Fan Yuan,et al.Protection of antioxidant system of EGCG on the thyroid in rat model from 131I radiation damage[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):311.[doi:10.3760/cma.j.issn.1673-4114.2015.04.009]
[11]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[12]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[13]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[14]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[15]孟召伟,谭建.解读美国甲状腺协会和临床内分泌医师协会2011年甲亢诊治指南[J].国际放射医学核医学杂志,2011,35(4):193.[doi:10.3760/cma.j.issn.1673-4114.2011.04.001]
MENG Zhao-wei,TAN Jian.Reading and analysis on management guidelines for hyperthyroidism published in 2011 by American Thyroid Association and American Association of Clinical Endocrinologists[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(3):193.[doi:10.3760/cma.j.issn.1673-4114.2011.04.001]
[16]王春梅,王雪梅.131I治疗甲亢的现状和研究进展[J].国际放射医学核医学杂志,2010,34(1):31.[doi:10.3760/cma.j.issn.1673-4114.2010.01.008]
WANG Chun-mei,WANG Xue-mei.The development and current status of 131I treatment for hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(3):31.[doi:10.3760/cma.j.issn.1673-4114.2010.01.008]
[17]孙琦婷,赵德善.Graves病甲状腺功能亢进症与血糖代谢[J].国际放射医学核医学杂志,2010,34(3):143.
SUN Qi-ting,ZHAO De-shan.Graves disease hyperthyroidism and glycometabolism[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(3):143.
[18]冯菲,赵德善.131I治疗青少年儿童甲状腺功能亢进症[J].国际放射医学核医学杂志,2009,33(3):171.[doi:10.3760/cma.j.issn.1673-4114.2009.03.011]
FENG Fei,ZHAO De-shan.The treatment of hyperthyroidism in adolescents and children with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(3):171.[doi:10.3760/cma.j.issn.1673-4114.2009.03.011]
[19]汤建林,李玉莹,高柳艳,等.甲状腺功能亢进症治疗方法的比较和选择[J].国际放射医学核医学杂志,2009,33(3):175.[doi:10.3760/cma.j.issn.1673-4114.2009.03.012]
TANG Jian-lin,LI Yu-ying,GAO Liu-yan,et al.The methods and options of the treatment for hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(3):175.[doi:10.3760/cma.j.issn.1673-4114.2009.03.012]
[20]王长修.甲状腺功能亢进症患者再次131I治疗的给药剂量对比研究[J].国际放射医学核医学杂志,2009,33(3):182.[doi:10.3760/cma.j.issn.1673-4114.2009.03.016]